Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759745 | 1.00 | CCNT1 (0.33) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL29759898 | 0.97 | CHRM1 (0.35) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL27185207 | 0.97 | CHRM1 (0.35) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL29759504 | 0.91 | CHRM1 (0.40) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL24577425 | 0.91 | CHRM1 (0.40) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL24577464 | 0.90 | WNT3A (0.34) | CCNT1CDK9HRH3IRAK4RAF1 | |
| SCHEMBL24578250 | 0.89 | WNT3A (0.34) | CCNT1CDK9HRH3IRAK4RAF1 | |
| SCHEMBL29759701 | 0.88 | POLQ (0.35) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL24577374 | 0.88 | POLQ (0.35) | CCNT1CDK9CHRM1PDGFRAHRH3 | |
| SCHEMBL24577467 | 0.87 | IRAK4 (0.33) | CCNT1CDK9CHRM1PDGFRAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |